STOCK TITAN
  1. Home
  2. News
  3. CNTB

Connect Biopharma Holdings Limited American Depositary Shares - CNTB STOCK NEWS

Welcome to our dedicated page for Connect Biopharma Holdings American Depositary Shares news (Ticker: CNTB), a resource for investors and traders seeking the latest updates and insights on Connect Biopharma Holdings American Depositary Shares stock.

Connect Biopharma Holdings Limited (Nasdaq: CNTB) is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases. The company is headquartered in Taicang, China, and has a significant presence in San Diego, CA. Connect Biopharma leverages its expertise in T cell biology to develop next-generation immune modulators for treating serious autoimmune diseases and inflammation.

Connect Biopharma's core business revolves around the discovery and development of small molecules and antibodies targeting critical pathways of inflammation. The company has built a robust portfolio of drug candidates, including:

  • Rademikibart (CBP-201): An antibody targeting interleukin-4 receptor alpha (IL-4Rα), developed for treating atopic dermatitis (AD) and asthma.
  • Icanbelimod (CBP-307): A modulator of S1P1 T cell receptors, designed for the treatment of ulcerative colitis (UC).
  • CBP-174: An investigational antagonist of histamine receptor 3, aimed at managing pruritus associated with AD.

Recent achievements include a strategic partnership with Simcere Pharmaceutical Co., Ltd. for the development and commercialization of rademikibart in Greater China. This collaboration includes an upfront payment of ¥150 million RMB (approximately US$21 million) and potential milestone payments up to ¥875 million RMB (approximately US$120 million), along with royalties.

Connect Biopharma’s financial condition is supported by its ongoing clinical trials and strategic partnerships. The company aims to complete rademikibart’s clinical trials for AD in China by the end of Q1 2024, with a new drug application submission planned thereafter.

The company has a deep commitment to leveraging functional T cell assays to screen and discover potent product candidates, aiming to provide innovative treatments for patients suffering from autoimmune and inflammatory diseases worldwide. For more information, visit Connect Biopharma.

News

Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma

Rhea-AI Summary
Connect Biopharma Holdings Limited (Nasdaq: CNTB) announced positive topline results from the global Phase 2b trial evaluating rademikibart efficacy and safety in adult patients with moderate-to-severe persistent asthma. The trial met its primary endpoint, showing significant improvement in lung function at Week 12 with both doses of rademikibart. The study demonstrated strong and significant improvement in asthma control, with both doses showing early and sustained improvement through Week 24. The safety results suggest rademikibart was generally well tolerated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.11%
Tags
clinical trial
-
News

Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023

Rhea-AI Summary
Connect Biopharma Holdings Limited (Nasdaq: CNTB) will present top-line data from the global Phase 2b trial evaluating rademikibart’s efficacy and safety in patients with moderate-to-severe asthma on December 12, 2023, before market open. The Company will host a conference call and webcast presentation at 8:30 a.m. ET to discuss the top-line data, featuring Dr. Edward M. Kerwin, MD, Founder and Senior Medical Director of the Clinical Research Institute, Allergy and Asthma Center and Altitude Clinical Consulting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.11%
Tags
clinical trial
-
News

Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China

Rhea-AI Summary
Connect Biopharma (CNTB) and Simcere Pharmaceutical (PR: Simcere Pharmaceutical Group Ltd.) have entered into an exclusive license and collaboration agreement for the development and commercialization of rademikibart in Greater China. Rademikibart is a human monoclonal antibody against IL-4Rα, a common subunit for IL-4R and IL-13 receptors being developed for the treatment of Th2 driven inflammatory diseases. Connect Biopharma will receive a ¥150 million RMB (US$ 21 million) upfront payment, up to ¥875 million RMB (US$ 120 million) upon achieving certain development and commercial milestones, in addition to royalties up to low double-digit percentages of net sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-38.83%
Tags
none
News

Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis

Rhea-AI Summary
Connect Biopharma Holdings Limited (CNTB) announced positive topline results from the Stage 2 of its China pivotal trial evaluating rademikibart’s efficacy and safety in patients with moderate-to-severe atopic dermatitis (AD). Rademikibart continued to be well tolerated over 52 weeks of treatment, with approximately 90% of patients on Q4W dose maintaining both IGA 0/1 and EASI-75 through Week 52.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-38.83%
Tags
none
-
News

Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023

Rhea-AI Summary
Connect Biopharma Holdings Limited (Nasdaq: CNTB) announces topline results from the Stage 2 of its China pivotal trial evaluating rademikibart’s efficacy and safety in patients with moderate-to-severe atopic dermatitis. The company will host a conference call and webcast presentation to discuss the trial results on Tuesday, November 21, 2023, at 8:30 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-38.83%
Tags
none
-
News

Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update

Rhea-AI Summary
Connect Biopharma reports financial results and provides business update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.9%
Tags
earnings
News

Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

Rhea-AI Summary
Connect Biopharma Holdings received a letter from Nasdaq indicating that its bid price for ADSs had closed below the minimum $1.00 per share requirement for continued listing. The company has until March 11, 2024, to regain compliance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
none
-
News

Connect Biopharma to Participate in Upcoming September Investor Conferences

Rhea-AI Summary
Connect Biopharma to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News

Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
none
News

Connect Biopharma to Participate in the SVB Securities Therapeutics Forum

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.61%
Tags
conferences

FAQ

What is the current stock price of Connect Biopharma Holdings American Depositary Shares (CNTB)?

The current stock price of Connect Biopharma Holdings American Depositary Shares (CNTB) is $1.02 as of January 22, 2025.

What is the market cap of Connect Biopharma Holdings American Depositary Shares (CNTB)?

The market cap of Connect Biopharma Holdings American Depositary Shares (CNTB) is approximately 56.8M.

What is Connect Biopharma Holdings Limited?

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on developing treatments for chronic inflammatory diseases using next-generation immune modulators.

What are Connect Biopharma's key drug candidates?

Their key drug candidates include rademikibart (CBP-201) for atopic dermatitis and asthma, icanbelimod (CBP-307) for ulcerative colitis, and CBP-174 for pruritus associated with atopic dermatitis.

Where is Connect Biopharma headquartered?

Connect Biopharma is headquartered in Taicang, China, with a significant presence in San Diego, California.

What is the latest news about Connect Biopharma?

Connect Biopharma recently entered into a strategic partnership with Simcere Pharmaceutical Co., Ltd. to develop and commercialize rademikibart in Greater China.

What are the financial terms of the partnership with Simcere?

The partnership includes an upfront payment of ¥150 million RMB (approximately US$21 million) and potential milestone payments up to ¥875 million RMB (approximately US$120 million), along with royalties.

What are the current projects of Connect Biopharma?

Current projects include completing rademikibart’s clinical trials for atopic dermatitis in China and preparing for a new drug application submission by the end of Q1 2024.

How does Connect Biopharma discover new drug candidates?

Connect Biopharma uses functional T cell assays to screen and discover potent product candidates against validated immune targets.

What diseases is Connect Biopharma targeting?

Connect Biopharma targets serious autoimmune diseases and chronic inflammatory conditions, including atopic dermatitis, asthma, and ulcerative colitis.

Who are the key partners of Connect Biopharma?

One of the key partners is Simcere Pharmaceutical Co., Ltd., which collaborates on the development and commercialization of rademikibart in Greater China.

Where can I find more information about Connect Biopharma?

More information can be found on their official website at Connect Biopharma.
Stock CNTB logo
Connect Biopharma Holdings Limited American Depositary Shares

Nasdaq:CNTB

CNTB Rankings

#4844 Ranked by Market Cap
N/A Ranked by Dividends

CNTB Stock Data

56.80M
32.51M
41.16%
44.43%
0.16%
Biotechnology
Healthcare
Link
United States of America
San Diego